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Abstract. Six palladium(II) and palladium(IV) complexes with 3-ethyl-5-methyl-5-(4-pyridyl)hydantoin, 
3-propyl-5-methyl-5-(4-pyridyl)hydantoin and 3-benzyl-5-methyl-5-(4-pyridyl)hydantoin were synthe-
sized. The complexes were identified and characterized by elemental analysis, IR, 1H, 13C NMR spectra 
etc. On the data obtained the molecular formulae of the new palladium complexes were proposed. The  
cytotoxicity of the complexes was evaluated in vitro using a panel of human tumour cell lines. The results 
demonstrate that the Pd(II) complex with 3-benzyl-5-methyl-5-(4-pyridyl)hydantoin exerts cytotoxicity as 
compared to the other studied Pd(II) complexes in all tested cell lines.  
Keywords: Pd(II) and Pd(IV) complexes, 3,5-disubstituted hydantoins, cytotoxicity  
 
INTRODUCTION 
In recent years much research efforts have been focused 
upon the design and development of innovative 
antineoplastic transition metal complexes with superior 
antiproliferative activity than cisplatin. Cisplatin is a 
widely used drug in cancer chemotherapy,1−4 but a wide 
range of side effects5 have limited its clinical usefulness. 
For this reason research has been extended to other 
metal complexes. On the basis of the structural analogy 
between platinum(II) and palladium(II) complexes, a 
variety of studies on palladium(II) complexes as poten-
tial anticancer drugs have been carried out.6 
Among the first to be used for clinical trials 
against tumors, were the analogous to cisplatin,  
complexes of Pd(II), cis-[Pd(En)Cl2] and cis-
[Pd(DACH)2Cl2] because Pd(II) has a very similar  
coordination chemistry to Pt(II), capable of forming 
square planar complexes. But these complexes have 
lower antitumor activity when compared to the analo-
gous Pt(II) complexes, as well as their high toxicity.7 In 
general the use of Pd(II) complexes in medicine is lim-
ited. However, Pd(II) N, S chelates with inert ligands 
(e.g. sulfur or nitrogen) were suggested by Das and 
Livingstone8 to be more effective antitumor agents than 
those of other metals, they possess the proper lability to 
bring the metal to the target (DNA) and allow it to  
interact with it. Palladium(II) complexes are much more 
labile than corresponding platinum(II) complexes, the 
lability of central palladium(II) may be much lower 
because of the shielding effect.9 Palladium(II)  
compounds might materialize the concept of tumor 
targeting, which would result in drugs with other  
spectrum of activity and a lack of cross-resistance as 
compared with platinum drugs.10 
The present study represents the synthesis,  
physicochemical evaluation and pharmacological  
investigation of Pd(II) and Pd(IV) complexes with 3-
ethyl-5-methyl-5-(4-pyridyl)hydantoin, 3-propyl-5-
methyl-5-(4-pyridyl)hydantoin and 3-benzyl-5-methyl-
5-(4-pyridyl)hydantoin. As a part of our drug discovery 
program to develop more effective palladium based 
anticancer drugs, here we report the antiproliferative 
activity of some Pd(II) and Pd(IV) complexes. 
 
EXPERIMENTAL 
Materials and Physical Measurements  
Potassium tetrachloropalladate(II) and potassium 
hexachloropalladate(IV) were purchased from Aldrich - 
USA. All other chemicals were of analytical grade. 
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The ligands 3-ethyl-5-methyl-5-(4-pyridyl)-hydan-
toin (L1), 3-propyl-5-methyl-5-(4-pyridyl)-hydantoin 
(L2) and 3-benzyl-5-methyl-5-(4-pyridyl)-hydantoin 
(L3) were prepared by alkylation of 5-methyl-5-(4-
pyridyl)-hydantoin, according to the published method 
[11]. The obtained compounds are new substances with 
the following melting points: L1 - 126−127 ºC, L2 - 
85−86 ºC and L3 - 158−159 ºC. Their Pd(II) complexes 
were synthesized using reported procedure with minor 
revisions.12,13 
CHN analysis was performed by “EuroEA 
EuroVector apparatus in the Inorganical Services  
Laboratory in the Faculty of Pharmacy of the Medical 
University of Sofia, Bulgaria. 
The IR spectra were recorded on Thermo Scien-
tific Nicolet iS10 spectrophotometer in the range of 
4000−400 as pellets KBr and on IFS 113 v Bruker FTIR 
spectrophotometer in the range of 400−150 cm−1 in 
polyethylene. 
The 1H and 13C NMR spectra were registered on a 
Bruker WM 250 (250 MHz) spectrometer in DMSO-d6. 
 
Synthesis of Pd(II) Complexes  
Synthesis of cis-[Pd(L1)2Cl2]·H2O (1) 
A water-ethanol solution of L1 (0.1259 g,  
0.6112 mmol) was added dropwise to water solution of 
K2[PdCl4] (0.1010 g, 0.3094 mmol). The mixture was 
stirred for 1−2 hours then the precipitate was filtered 
off, washed with distilled water and dried under  
vacuum. The substance is soluble in DMSO, DMF and 
weakly soluble in water and ethanol. Yield 68 %,  
m.p.: > 230 ºC (dec.). 
IR (KBr disc. and polyethylene,  / cm−1): 3438, 
3301, 1784, 1719, 1658, 1617, 1452, 1427, 369, 318.  
1H NMR (DMSO-d6, δ / ppm): 9.05 (s,1H, NH-1), 
8.77 (d, 2H, J  = 7 Hz, H-2 + H-6), 7.66 (d, 2H, J = 7Hz, 
H-3 + H-5), 3.37 (q, 2H, J = 7Hz, N-СH2), 1.69 (s, 3H, 
CH3–C-5); 1.06 (t, 3H, J = 7Hz, N-CH2-CH3).  
13С NMR (DMSO-d6, δ / ppm): 173.3 (C=O-4’), 
155.3 (C=O-2’), 153.1 (C-2 + C-6), 151.6 (C-4), 122.3 
(C-3 + C-5), 62.2 (C-5’), 33.3 (N-СH2),  24.6 (CH3), 
13.1 (N-CH2-CH3). 
Synthesis of cis-[Pd(L2)2Cl2] (2) 
The complex cis-[Pd(L2)2Cl2]·2H2O (2) was synthe-
sized analogously to the procedure for complex 1. The 
substance is soluble in DMSO, DMF and weakly solu-
ble in water and ethanol. Yield 68 %, m.p.: > 230 ºC 
(dec.). 
IR (KBr disc. and polyethylene,  / cm−1): 3302, 
1780, 1720, 1618, 1455, 1425, 371, 355. 
1H NMR (DMSO-d6, δ / ppm): 9.04 (s,1H, NH-1), 
8.76 (d, 2H, J = 7Hz, H-2 + H-6), 7.66 (d, 2H, J = 7Hz, 
H-3 + H-5), 3.32 (q, 2H, J = 7Hz, N-СH2), 1.69 (s, 3H, 
CH3–C-5); 1.49 (sxt, 2H, J = 7 Hz, N-CH2-CH2), 0.76 
(t, 3H, J = 7Hz, N-CH2-CH2-CH3). 
13С NMR (DMSO-d6, δ / ppm): 173.5 (C=O-4’), 
155.4 (C=O-2’), 153.1 (C-2 + C-6), 151.5 (C-4), 122.2 
(C-3 + C-5), 62.1 (C-5’),  39.5 (N-СH2),  24.6 (CH3), 
20.7 (N-CH2-CH2), 10.9 (N-CH2-CH2-CH3). 
 
Synthesis of cis-[Pd(L3)2Cl2]·H2O (3) 
The complex cis-[Pd(L3)2Cl2].H2O was synthesized 
analogously to the procedure for complex 1. 
The substance is soluble in DMSO, DMF  
and weakly soluble in water and ethanol. Yield 74 %, 
m.p.: > 188 ºC (dec.). 
IR (KBr disc. and polyethylene,  / cm−1): 3282, 
1784, 1717, 1616, 1495, 1441. 
1H NMR (DMSO-d6, δ / ppm): 9.18 (s,1H,  
N(1)-H), 8.77 (d, 2H, 3JH,H = 7Hz, H-2 + H-6), 7.66 (d, 
2H, 3JH,H = 7Hz, H-3 + H-5), 7.30−7.16 (m, 5H, C6H5),  
4.54 (s, 2H, N-CH2), 1.68 (s, 3H, CH3−C-5). 
13С NMR (DMSO-d6, δ / ppm): 173.5 (C=O-4’), 
155.3 (C=O-2’), 153.2 (C-2 + C-6), 151.4 (C-4), 136.3 
(C-1, benzene), 128.7 (C-2 + C-6, benzene), 127.6 (C-4, 
benzene), 127.1 (C-3 + C-5, benzene), 122.4 (C-3 + C-5), 
62.5 (C-5’),  24.8 (CH3). 
 
Synthesis of Pd(IV) Complexes 
Synthesis of cis-[Pd(L1)2Cl4]  (1a) 
A water-ethanol solution of L1 (0.1110 g,  
0.5068 mmol) was added dropwise to water solution of 
K2[PdCl6] (0.1006 g, 0.3082 mmol). The mixture was 
stirred for 1−2 hours then the precipitate was filtered 
off, washed with distilled water and dried under  
vacuum. The substance is soluble in DMSO, DMF  
and weakly soluble in water and ethanol. Yield 74 %, 
m.p.: > 275 ºC (dec.). 
IR (KBr disc. and polyethylene,  / cm−1): 3469, 
3303, 1784, 1719, 1617, 1452, 1426. 
1H NMR (DMSO-d6, δ / ppm): 9.05 (s, 1H,  
N(1)-H), 8.78 (d, 2H, J = 7Hz, H-2 + H-6), 7.67 (d, 2H,  
J = 7Hz, H-3 + H-5), 3.32 (t, 2H, J = 7Hz, N-CH2),   
1.70 (s, 3H, CH3–С-5’), 1.51 (sxt, 2H, J = 7 Hz, N-CH2-
CH2), 0.77 (t, 3H, J = 7Hz, N-CH2-CH2-CH3). 
13С NMR (DMSO-d6, δ / ppm): 173.5 (C=O-4’), 
155.4 (C=O-2’), 153.1 (C-2 + C-6), 151.5 (C-4), 122.2 
(C-3 + C-5), 62.1 (C-5’), 39.5(N-CH2), 24.6 (CH3–C-5), 
20.7 (N-CH2-CH2), 10.9 (N-CH2-CH2-CH3). 
 
Synthesis of cis-[Pd(L2)2Cl4]  (2a) 
The complex cis-[Pd(L2)2Cl4] (2a) was synthesized 
analogously to the procedure for complex 4. The  
substance is soluble in DMSO, DMF and weakly  
soluble in water and ethanol. Yield 64 %, m.p.: > 185 ºC 
(dec.). 
IR (KBr disc. and polyethylene,  / cm−1): 3322, 
1784, 1719, 1618, 1427. 
1H NMR (DMSO-d6, δ / ppm): 9.05 (s,1H,  
N(1)-H), 8.78 (d, 2H, J = 7Hz, H-2 + H-6), 7.67 (d, 2H,  
J = 7Hz, H-3 + H-5), 3.32 (t, 2H, J = 7Hz, N-CH2),  
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1.70 (s, 3H, CH3–С-5’), 1.51 (sxt, 2H, J = 7 Hz,  
N-CH2-CH2), 0.77 (t, 3H, J = 7Hz, N-CH2-CH2-CH3). 
13С NMR (DMSO-d6, δ / ppm): 173.5 (C=O-4’), 
155.4 (C=O-2’), 153.1 (C-2 + C-6), 151.5 (C-4), 122.2 
(C-3 + C-5), 62.1 (C-5’), 39.5 (N-CH2), 24.6 (CH3–C-5), 
20.7 (N-CH2-CH2), 10.9 (N-CH2-CH2-CH3). 
 
Synthesis of cis-[Pd(L3)2Cl4]  (3a) 
The complex cis-[Pd(L3)2Cl4] (3a) was synthesized 
analogously to the procedure for complex 4. Yield:  
74 %, m.p.: > 172 ºC (dec.). 
IR (KBr disc. and polyethylene,  / cm−1): 3286, 
1780, 1718, 1617, 1497, 1441, 377, 354. 
1H NMR (DMSO-d6, δ / ppm): 9.21 (s,1H,  
N(1)-H), 8.78 (d, 2H, 3JH,H = 7Hz, H-2 + H-6), 7.68 (d, 
2H, 3JH,H = 7Hz, H-3 + H-5), 7.34−7.17 (m, 5H, C6H5),  
4.55 (s, 2H, N-CH2), 1.72 (s, 3H, CH3–C-5’). 
13С NMR (DMSO-d6, δ / ppm): 173.4 (C=O-4’), 
155.3 (C=O-2’), 153.2 (C-2 + C-6), 151.4 (C-4), 136.3 
(C-1, benzene), 128.7 (C-2 + C-6, benzene), 127.6 (C-4, 
benzene), 127.1 (C-3 + C-5, benzene), 122.3 (C-3 + C-5), 
62.5 (C-5’), 24.8 (CH3). 
All the data about molecular formulae, formula 
weights, colors and the contents of nitrogen, carbon and 
hydrogen are given in Table 1. 
 
Pharmacology 
The present study describes a comparative evaluation of 
the cytotoxic effects of six newly synthesized Pd(II) and 
Pd(IV) complexes with some 3,5-disubstituted hydan-
toins vs. the referent antineoplastic agent cisplatin on a 
panel of human tumor cell lines, using the standard 
MTT-dye reduction assay for cell viability. 
 
Cell Culture Conditions 
The following cell lines were used for the experiments: 
(i) SKW-3 or a KE-37 derivative (human T-cell leuke-
mia, established from the peripheral blood of a 61-year-
old man with T-cell lymphocytic leukemia); (ii) HL-60 
(acute myeloid leukemia, established from the peripher-
al blood of a patient with acute promyelocyte leukemia); 
(iii) EJ (human urinary bladder carcinoma), (iv) LAMA-
84 (human chronic myeloid leukemia, established from 
the peripheral blood of a 29-year-old woman with 
chronic myeloid leukemia). The cell lines were main-
tained as suspension-type (SKW-3, LAMA-84, HL-60) 
or adherentmonolayer-type cultures (EJ) in cell-culture 
flasks using RPMI-1640, supplemented with 10 % heat-
inactivated fetal calf serum and L-glutamine as a growth 
medium. The cells were incubated in a controlled  




Cytotoxicity of the compounds was assessed using the 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide] dye reduction assay as described by 
Mossman14 with some modifications.15 Exponentially 
growing cells were seeded in 96-well microplates  
(100 L / well at a density of 3.5105 cells / mL for the 
adherent and 1105 cells / mL for the suspension  
cell lines) and allowed to grow for 24 h prior the expo-
sure to the studied compounds. Stock solutions of the 
palladium complexes were freshly prepared in DMSO 
and then diluted with corresponding growth medium.  
At the final dilutions the solvent concentration never 
exceeded 0.5 %. Cells were exposed to the tested agents 
for 72 h, whereby for each concentration a set of  
8 separate wells was used. Every test was run in  
triplicate, i.e. in three separate microplates. After  
incubation with the tested compounds MTT solution  
(10 mg / mL in PBS) aliquots were added to each well. 
The plates were further incubated for 4 h at 37 ºC and 
the formazan crystals formed were dissolved by adding 
110 L of 5 % HCOOH in 2-propanol. Absorption of 
the samples was measured by an ELISA reader  
(Uniscan Titertec) at 580 nm. Survival fraction was 
calculated as percentage of the untreated control.  
The experimental data were processed using GraphPad 
Prizm software and were fitted to sigmoidal concentra-
tion/response curves, using non-linear regression  
analysis. 
Table 1. Physical properties and elemental analysis of new palladium complexes 
Complex 
Molecular formula 
(Formula weight)  Colour 
Elemental analysis: 
Calc. % (Found) 
C H N 
cis-[Pd(L1)2Cl2]·H2O C22H28N6O5Cl2Pd (633.3) Light yellow 41.69 (41.33) 4.42 (4.50) 13.26 (13.41) 
cis-[Pd(L2)2Cl2] C24H30N6O4Cl2Pd (643.3) Lemon yellow 44.77 (44.55) 4.66 (4.35) 13.06 (11.23) 
cis-[Pd(L3)2Cl2] C32H32N6O5Cl2Pd (741.3) Light yellow 50.80 (50.72) 4.32 (4.08) 11.33 (11.32) 
cis-[Pd(L1)2Cl4] C22H26N6O4Cl4Pd (686.2) Light yellow 38.47 (39.16) 3.79 (4.02) 12.24 (12.56)  
cis-[Pd(L2)2Cl4] C24H30N6O4Cl4Pd (714.2) Light yellow 40.33 (41.29) 4.20 (4.48) 11.76 (11.75) 
cis-[Pd(L3)2Cl4] C32H32N6O4Cl4Pd(812 .2) Light yellow 47.28 (47.63) 3.94 (3.91) 10.34 (10.61) 
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RESULTS AND DISCUSSION 
Chemical Studies  
Complexes (1), (2) and (3) were prepared by adding of 
water-ethanol solutions of ligands L1, L2 and L3 to  
the water solution of K2[PdCl4] in molar ratio 1 : 2. 
Complexes (1a), (2a) and (3a) were prepared by adding 
of water-ethanol solutions of ligands L1, L2 and L3 to 
the water solution of K2[PdCl6] in the same ratio.  
The mixtures were stirred for 1−2 hours then the precip-
itates were filtered off, washed with distilled water  
and dried under vacuum. The substances are soluble in 
solvents with pronounced donor properties, such as 
N,N-dimethyl-formamide, dimethylsulfoxide and weak-
ly soluble in water and ethanol. 
 
IR Spectroscopy 
Infrared spectroscopy data confirm the coordination of 
ligands to the palladium(II) and palladium(IV) ions via 
nitrogen atom from pyridine ring of the ligands. In the 
spectra of the ligands L1, L2 and L3 the typical stretch-
ing vibrational mode of substituted pyridines, ν(C=N) 
for the uncoordinated ligands is appeared at 1600 сm−1 
and were blue shifted to higher wavenumbers - 1658, 
1618, 1616, 1617, 1618 and 1617 cm−1 in the spectra of 
the complexes - respectively. The other characteristic 
bands from the pyridine ring of the metal-free ligands 
are again blue-shifted upon complexation. These shifts 
were in agreement with the N-coordination, involving 
the pyridine N atom of the ligands. New bands in the 
range of 377–318 cm−1 were assigned to the ν(Pt–Cl) 
stretching vibrations. In the IR spectra of the all com-
plexes two bands for ν(Pt–Cl) stretching vibrations were 
observed, implying cis-location of chloride ligands.16 
The bands related to the stretching vibrations of 
the two carbonyl groups in the metal-free ligands did 
not shift upon coordination of L1, L2 and L3 to palladi-
um(II) and palladium(IV) ions, indicating that the C=O 




The 1H NMR spectra of the freshly prepared DMSO-d6 
solutions of the ligands and complexes were recorded. 
In the spectra of complexes 1, 2 and 3 the signals of the 
protons for Н-2 and Н-6 from the pyridine ring were 
shifted from 8.61 ppm in the ligands L1−L3 to  
8.77, 8.76, 8.77, 8.78, 8.78 and 8.78 ppm in the com-
plexes 1−3 and 1a−3a. The differences between the 
chemical shifts of the protons of the ligands L1−L3 and 
those of the corresponding complexes are in the range 
of 0.15–0.17 ppm for all studied complexes. The signals 
of the Н-3 and Н-5 protons from the pyridine ring were 
shifted from 7.48 ppm in the ligands L1–L3 to  
7.66, 7.66, 7.66, 7.67, 7.67 and 7.68 ppm in the  
complexes 1–3 and 1a−3a respectively. Here the  
differences are in the range of 0.18–0.20 ppm. All  
signals for the protons in the pyridine ring were shifted. 
This shows that the most probable bounding of the  
ligands with the palladium ions in all complexes is  
realized through the nitrogen atom from the pyridine 
ring. 
 
13C NMR Spectra 
In the 13C NMR spectra of the compounds 1–3 and 
1a−3a the signals for the carbon atoms C-2 and С-6 
from the pyridine ring were at 153.1, 153.1, 153.2, 
153.1, 153.1 and 153.2 ppm, respectively, compared to 
150.0 ppm for the metal-free ligands L1−L3. The down-
field chemical shifts in the range 3.1 to 3.2 ppm indicate 
that the pyridine nitrogen atom takes part in the coordi-
nation to the metal ions. The shifts of the С-3 and С-5 
were smaller in according to their remote positions from 
the binding nitrogen atom. 
The resonances of the two С=О groups of the 
hydantoin ring in metal-free-ligands L1, L2 and L3 and 
in their complexes 1–3 and 1a−3a were the practically 
same. This shows that the hydantoin ring is not involved 
in the coordination with the metal ion. 
The elemental analysis and spectroscopic data 
confirm the following structures of the complexes 
shown in Figure 1. 
 
Pharmacology 
In vitro Cytotoxicity 
The tested palladium(II) and palladium(IV) complexes 
exerted cytotoxic effects after 72 h continuous exposure, 
whereby the individual chemosensitivity varied among 
the different cell lines, as evidenced by the IC50 values, 
summarized in Table 2.  
The Pd(II) complex with 3-benzyl-5-methyl-5-(4-
pyridyl)hydantoin (3) proved to be the most active  
analogue within this series, whose antiproliferative 
potency in SKW-3 was relative to that of the reference 
antineoplastic drug cisplatin. 
Figure 1. Chemical structures of studied Pd(II) and Pd(IV)
complexes. 
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CONCLUSION 
Six Pd(II) and Pd(IV) complexes with 3-ethyl, 3-propyl- 
and 3-benzyl-5-methyl-5-(4-pyridyl)hydantoins were 
synthesized according to procedures described in the 
literature. All complexes were characterized by ele-
mental analysis, IR, 1H, 13C NMR spectra. The mode of 
the coordination of the ligands with palladium ions is 
realized via the nitrogen atom of the pyridine ring. The 
coordination mode is identical to those of Pt(II) and 
Pt(IV) complexes with the same ligands, described in 
our preceding reports. The cytotoxicity of the prersented 
palladium complexes was assessed in vitro on a panel of 
four human tumour cell lines. The results show that the 
Pd(II) and Pd(IV) complexes with 3-benzyl-5-methyl-5-
(4-pyridyl)hydantoin possess higher cytotoxicity in all 
cell lines than the other Pd(II) and Pd(IV) complexes 
with 3-ethyl- and 3-propyl-5-methyl-5-(4-pyridyl)hy-
dantoins. This is in keeping with the Pt(II) (where for 
Pt(II) complexes cytotoxicity was strongly dependent on 
their calculated logP values) and Pt(IV) complexes with 
the same ligands. 
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Table 2. Cytotoxicity of all studied Pd(II) and Pd(IV)  
complexes 1−3 and 1a−3a in comparison to cisplatin in four 
human tumour cell lines 
 IC50 values / µM 
Cell line SKW-3(a) HL-60(b) EJ(c) LAMA-84(d) 
Complex 1 149.2 > 200 162.3 > 200 
Complex 2 − > 200 137.5 165.8 
Complex 3 49.5 134.2 99.7 117.2 
Complex 1a 147.7 > 200 > 200 > 200 
Complex 2a − 194.1 125.8 160.8 
Complex 3a 139.7 153.0 88.6 119.4 
Cisplatin 11.4 8.7 10.2 16.9 
(a) T-cell leukemia.  
(b) Acute myeloid leukemia. 
(c) Urinary bladder carcinoma. 
(d) Human chronic myeloid leukemia. 
